Funding of just under £50k from IBioIC enabled Ingenza to gain invaluable expertise and enhanced their ability to access new markets and end users thanks to the technology developed as a result of this project.

A new predictive model for more efficient production of proteins as pharmaceuticals, industrial biocatalysts or numerous other engineering biology applications.

In this project, IBioIC funded a team of scientists at Edinburgh University to work with ILC Therapeutics to develop a platform that could produce hybrid proteins, based on the Type 1 Interferons, with enhanced cancer fighting capabilities.

Glycoproteins made using yeast have the potential to significantly reduce the cost of treatments for the NHS.

IBioIC funded a collaboration between 3F BIO and the University of Strathclyde to develop and test a sustainable protein production process which advanced the company's progress towards commercialisation.

3F BIO delivered their 18-month Proof of Concept programme whilst commissioning their equipment and operating systems within RapidBio, our facility in Glasgow.